FDA Moves to Restrict Compounded Versions of Popular Weight Loss and Diabetes Drugs

The U.S. Food and Drug Administration (FDA) has taken a significant step that could reshape access to some of the most sought-after medications for obesity and diabetes. The agency proposed removing the active ingredients in top-selling drugs like Wegovy, Ozempic, Mounjaro, and Zepbound from a special list that allows large-scale compounding facilities to produce cheaper, unapproved versions. This decision, which favors drugmakers Novo Nordisk and Eli Lilly, stems from a determination that these compounded products no longer meet legal criteria for clinical need. Below, we explore the implications through key questions and answers.

What exactly did the FDA propose regarding weight loss and diabetes drugs?

The FDA suggested striking semaglutide and tirzepatide from the list of substances that 503B outsourcing facilities can use to manufacture compounded medications in bulk. Semaglutide is the active ingredient in Novo Nordisk's Wegovy (for weight loss) and Ozempic (for diabetes), while tirzepatide is found in Eli Lilly's Mounjaro (diabetes) and Zepbound (obesity). These compounding facilities are not standard pharmacies; they are larger operations that produce medicines without individual prescriptions, often to fill supply gaps or offer lower-cost alternatives. The proposal would effectively prohibit them from making large quantities of drugs containing these ingredients.

Why did the FDA decide to exclude these drugs from the compounding list?

The agency concluded that there is no clinical need for bulk compounding of semaglutide and tirzepatide. Under federal law, 503B facilities can only compound substances that appear on a specific FDA list—known as the 503B Bulks List—if the ingredient is not otherwise available in an FDA-approved form, or if there is a documented medical necessity. According to the FDA, the approved brand-name versions of these drugs are now widely accessible (despite ongoing shortages for some doses), and the compounded versions have not demonstrated unique clinical advantages. The decision came after growing controversy over the role of compounders in making weight loss treatments available, often at lower prices but with greater regulatory uncertainty.

What are 503B compounding facilities, and how do they differ from regular pharmacies?

503B facilities, named after a section of the Federal Food, Drug, and Cosmetic Act, are large-scale outsourcing facilities that produce compounded drugs without requiring a prescription for each individual patient. Unlike traditional compounding pharmacies (see below), which make medications tailored to specific patients' needs, 503B facilities operate more like mini-manufacturers. They can produce batches of drugs in advance and distribute them to hospitals, clinics, and doctors' offices. However, they are subject to stricter FDA oversight, including current Good Manufacturing Practices (cGMP). The key legal difference is that 503B facilities can only use ingredients from the FDA's bulk drug list—a list that the agency now wants to strip of semaglutide and tirzepatide.

How does this decision benefit Novo Nordisk and Eli Lilly?

The proposal is a clear victory for both companies, which have seen their blockbuster drugs hit by shortages that spurred demand for compounded alternatives. Compounded versions typically cost less—sometimes hundreds of dollars less per month—cutting into profits from the branded products. By removing these ingredients from the 503B list, the FDA makes it much harder for compounders to legally produce mass quantities of semaglutide and tirzepatide. This could drive patients back to the brand-name drugs, boosting sales for Novo Nordisk and Eli Lilly. Additionally, it protects their intellectual property and pricing power, as compounders do not face the same research and marketing costs.

What does this mean for patients who rely on compounded versions?

For patients currently using compounded semaglutide or tirzepatide—often due to insurance gaps, high copays, or supply shortages—the future is uncertain. The FDA's proposal does not take effect immediately; it opens a public comment period. But if finalized, 503B facilities would be forced to stop making these products. Patients may have to switch to branded drugs, which could be significantly more expensive without insurance coverage. Some may turn to traditional compounding pharmacies that still operate on a patient-specific basis (under different regulations), but even those face restrictions. The FDA acknowledges that shortages of certain doses still exist, but it maintains that the approved drugs are generally available now, reducing the justification for bulk compounding.

What legal requirements did the compounders fail to meet?

For a substance to remain on the 503B bulks list, the FDA must determine that there is a clinical need for the compounded version that is not met by an FDA-approved drug. In its decision, the agency argued that the approved versions of semaglutide and tirzepatide adequately address patient needs, despite periods of limited supply. The FDA also noted that these compounded products have not been proven to be safer or more effective. Under the law, a lack of clinical need is sufficient grounds for removal. The decision effectively says that the convenience and lower cost of compounded drugs do not constitute a clinical need—a strict interpretation that has drawn criticism from patient advocacy groups and some healthcare providers.

What is the next step for this FDA proposal?

The FDA's proposal is not yet final; it was published for public comment, typically a 60- to 90-day period. During this time, stakeholders—including compounders, pharmaceutical companies, patient groups, and healthcare providers—can submit feedback. The FDA will then review the comments and issue a final rule, which could be implemented as early as late 2025. If finalized, the removal would take effect after a transition period, likely several months, to allow facilities to adjust. In the meantime, the FDA continues to monitor shortages and may reconsider if the supply situation worsens. This regulatory process highlights the ongoing tension between patient access to affordable medications and the incentives of brand-name drugmakers.